Patents Examined by Joseph Fischer
  • Patent number: 11896704
    Abstract: A compound of formula (1) R1—Wm—Xn-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp—Zq—R2, wherein AA1 is Phe; AA2 is Trp; AA3 is selected from Met, Leu and lie; AA4 is selected from Lys, Arg and Gln; AA5 is Arg; AA6 is Lys; AA7 is selected from Arg, Lys and His; AA8 is selected from Val, Ile, Leu and Met; and AA9 is Pro. The compound is useful in the treatment and/or care of the skin, hair, nails and/or mucous membranes, in particular for improving the barrier function of the skin, for energizing the skin and as an anti-aging agent.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: February 13, 2024
    Assignee: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Raquel Delgado Gonzalez, Núria Almiñana Domènech, Consuelo García Hernández, Mauricio Valerio Santiago, Antonio Ferrer Montiel, Wim Van Den Nest, Catalina Rodríguez Bielsa
  • Patent number: 11834486
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Patent number: 11819532
    Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: November 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Daniella Cheang, Patrick Di Giorgio, Patrizio Mattei, Petra Schmitz, Theodor Stoll
  • Patent number: 11795204
    Abstract: The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 24, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Lise Giehm
  • Patent number: 11795207
    Abstract: Modified hum1.an factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, P57, L69, I80, L178, R199, H212, I215, R269, I310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: October 24, 2023
    Assignee: AAVNERGENE INC.
    Inventors: Qizhao Wang, Daozhan Yu
  • Patent number: 11766480
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 26, 2023
    Assignee: NEW YORK UNIVERSITY
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian, Justin M. Holub
  • Patent number: 11673914
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
  • Patent number: 11666636
    Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 6, 2023
    Assignee: Vanderbilt University
    Inventors: Kevin Niswender, Stokes Peebles
  • Patent number: 11529394
    Abstract: The present disclosure provides a polypeptide conjugates comprising GLP-1 receptor agonist and a peptide linker, and pharmaceutical compositions comprising the same. Methods of using such for treating diseases are also provided.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: December 20, 2022
    Assignee: BEIJING QL BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yuanyuan Zhang, Xinle Wu, Haixia Zou, Peng Zhai, Yaoguang Jin, Bo Wu, Xu Chen, Wei Guo, Xinyu Zhao, Zuobin Wang, Lingli Zeng
  • Patent number: 11524977
    Abstract: An ultrasound-assisted simulated digestion method of a milk protein active peptide and an application thereof in health foods, pertaining to the technical field of intensive processing of dairy products and preparation of health foods. The method firstly employs ultrasonic pretreatment of casein and ?-lactoglobulin, followed by enzymatic hydrolysis with a protease to prepare casein and ?-lactoglobulin polypeptide, and traces the activity of the polypeptide by simulating gastrointestinal digestion, and then simulates absorption by intestinal epithelial cells with Caco-2 cells, to characterize a highly active milk protein polypeptide digested by the gastrointestinal tract and absorbed by the Caco-2 cells simulating absorption by the inner wall of the small intestine. The method has identified five such highly active milk protein polypeptides.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: December 13, 2022
    Assignee: JIANGSU UNIVERSITY
    Inventors: Xiaofeng Ren, Qiufang Liang, Haile Ma, Yuqing Duan, Ronghai He, Xiaoming Yang, Xi Zhang, Ting Hou, Xinxiang Chen
  • Patent number: 11505581
    Abstract: The specificity of CD4+ TH responses of German cockroach (Bla g) antigens, and whether differences exist in magnitude or functionality as a function of disease severity, is disclosed. Also disclosed are novel German cockroach allergens and epitopes.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: November 22, 2022
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Bjoern Peters, Alessandro Sette
  • Patent number: 11505583
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: November 22, 2022
    Assignee: Second Genome, Inc.
    Inventors: Cristina N. Butterfield, Daniela Keilberg, Andrew W. Goodyear, Andrew W. Han
  • Patent number: 11497795
    Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 15, 2022
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Takumi Sakai, Genichi Kusakawa, Yugo Uchida
  • Patent number: 11485759
    Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 1, 2022
    Assignee: University of Washington
    Inventors: David Baker, Jacob B. Bale, Neil P. King, William H. Sheffler, Daniel Ellis
  • Patent number: 11466062
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: October 11, 2022
    Assignee: MOLECULAR PARTNERS AG
    Inventors: Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
  • Patent number: 11453703
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 27, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
  • Patent number: 11402393
    Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 2, 2022
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
  • Patent number: 11376333
    Abstract: The present invention relates to a substrate for transglutaminase comprising a peptide having from 3 to 15 amino acids and comprising the amino acid sequence X?4X?3X?2X?1QX+1X+2X+3X+4, bound to a first molecule.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: July 5, 2022
    Assignee: COVALAB
    Inventors: Saïd El Alaoui, Vincent Thomas
  • Patent number: 11331366
    Abstract: The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 17, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Muneshige Shimizu, Akina Shiokawa, Koichiro Hamada, Kiyohiko Magata, Takeshi Nikawa, Ayako Maita
  • Patent number: 11332514
    Abstract: Herein is reported a method for purifying a polypeptide comprising the steps of i) applying a solution comprising the polypeptide to an ion exchange chromatography material, and ii) recovering the polypeptide with a solution comprising a denaturant and thereby purifying the polypeptide, whereby the ion exchange chromatography material comprises a matrix of cross-linked poly (styrene-divinylbenzene) to which ionic ligands have been attached, and wherein the solution comprising the polypeptide applied to the ion exchange chromatography material is free of the denaturant and the polypeptide adsorbed to the ion exchange chromatography material is recovered with a solution comprising a denaturant at a constant conductivity.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: May 17, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Falkenstein, Maria Laura Magri, Michaela Mehr, Klaus Schwendner, Bernhard Spensberger